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Background: Golgi protein 73 (GP73) is a type II Golgi transmembrane protein. It is over-expressed in several
cancers, including hepatocellular carcinomas, bile duct carcinomas, lung cancer and prostate cancer. However, there
are few reports of GP73 in gastric cancer. This study is aimed at investigating the expression of GP73 and its
relationship with clinical pathological characters in gastric cancer.
Methods: GP73 mRNA level was determined by quantitative real-time RT-PCR in 41 pairs of matched gastric
tumorous tissues and adjacent non-tumorous mucosal tissues. Western blotting was also performed to detect the
GP73 protein level. GP73 protein expression was analyzed by immunohistochemistry in 52 clinically characterized
gastric cancer patients and 10 non-tumorous gastric mucosal tissue controls.
Results: The mRNA and protein level of GP73 were significantly down-regulated in gastric tumorous tissues
compared with the non-tumorous mucosal tissues. In non-tumorous mucosa, strong diffuse cytoplasmic staining
can be seen in cells located at the surface of the glandular and foveolar compartment; while in tumorous tissues,
the staining was much weaker or even absent, and mainly in a semi-granular dot-like staining pattern. The
expression level of GP73 protein was associated with patients’ gender and tumor differentiation.
Conclusions: GP73 was normally expressed in non-tumorous gastric mucosa and down-regulated in gastric cancer.
Its expression in gastric cancer was correlated with tumor differentiation.
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GP73, also known as GOLM1 and GOLPH2, is a type II
Golgi transmembrane protein. Structurally, GP73 contains
a short N-terminal cytoplasmic domain, a transmembrane
domain and a larger luminal C-terminal domain which is
composed of a coiled-coil domain and an acid tail. The
luminal C-terminal domain is the major function domain
of GP73 [1-3]. Mice with a severe truncation of the GP73
C-terminus showed decreased survival and severe epithe-
lial abnormalities of the kidney and the liver [4]. The
coiled-coil domain could interact with both precursor and
mature sCLU, indicating that GP73 might assist in the
post-translational modification, transportation and secre-
tion of sCLU [5]. A proproteinconvertase recognition site
R52VRR55 is located within the C-terminal ectodomain;* Correspondence: zaiyuanye@163.com
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reproduction in any medium, provided the orPC-mediated cleavage of GP73 transforms the intracellu-
lar, Golgi-localized GP73 to a soluble, secretory protein
[6]. However, the function of GP73 is still unclear.
GP73 was first identified from a cDNA library derived
from the liver of a patient with adult giant-cell hepatitis.
It is considered an epithelial cell-specific protein, which
is highly expressed in the colon, stomach, prostate and
trachea in normal, healthy persons [1]. Liver disease, such
as virus infection and cirrhosis, could up-regulate the
expression of GP73 in hepatocytes [1,7,8]. Recent studies
showed that GP73 was over-expressed in several cancers,
such as hepatocellular carcinomas [9-11], bile duct carcin-
omas [11], lung adenocarcinomas [12], prostate cancer
[13,14] and seminomas [15]. The expression of GP73
in renal cancer is much more comprehensive. It was
reported as down-regulated in the majority of clear cell
renal cell cancers (RCCs), but highly-expressed in pap-
illary and chromophobe renal carcinomas [16]. Serumtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of clinicopathologic characteristics of
gastric cancer patients
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carcinomas, bile duct carcinomas and lung adenocar-
cinomas. It even showed an advantage over α-fetoprotein
(AFP) for diagnosing early hepatocellular carcinomas [17,18].
Also, mRNA expression of GP73 in urine outperformed
serum PSA in detecting prostate cancer [13].
Gastric cancer is one of the most common cancers
and the second leading cause of cancer-related death
worldwide. It has particularly high frequencies in China
[19]. Until now, the etiological factors and pathogenesis
of gastric cancer have not been fully understood. In this
study, we aim to investigate the expression of GP73 and
its relationship with clinical pathological characters in
gastric cancer by measuring the mRNA and protein ex-




Forty-one pairs of matched gastric tumorous and adjacent
non-tumorous mucosal tissues (>5cm from the edge of
the tumor)were obtained from patients with primary gas-
tric cancer at the Zhejiang Provincial People’s Hospital,
China from January 2011 to December 2012. The charac-
teristics of 41 GCsare shown in Table 1. After surgical re-
moval, tissues were frozen immediately in liquid nitrogen
and stored at −80°C until use.
Fifty-two paraffin specimens of gastric cancer (GC) tis-
sue (43 males, 9 females) were acquired from Zhejiang
Provincial People’s Hospital, collected from 2010 to 2011.
All cases of gastric cancer were classified according to the
WHO classification and staged by means of the pTNM
system [20]. The cases consisted of 22 patientsaged<60
years, 30 patients aged ≥60years; 20 patients with the
tumor size <5cm, 32 patients with the tumor size ≥5cm;
22 patients with moderately differentiated cancer, 30 pa-
tients with poorly differentiated cancer; 14 patients with
T1 or T2 wall invasion, 38 patients with T3 or T4 wall
invasion; 39 patients with lymph node metastasis and 13
patients without lymph node metastasis; 10 patients
with distant metastasis and 42 patients with no distant
metastasis. The numbers of patients classified by TNM
stage were as follows: 18 were at TNM stage I or II; 34
at TNM stage III or IV. The patients were between 32
and 84 years of age, and there was no radiotherapy or
chemotherapy prior to the operation. Specimens were
fixed by formalin and embedded in paraffin. Tennormal
tissue specimens of the stomach from patients without
malignant tumors were also obtained by endoscopy as
the control group.
All patients provided informed consent for the use of
their tissues before surgery. The use of all specimens
was approved by the ethics committee of Zhejiang
Provincial People’s Hospital.Quantitative real-time PCR
qRT-PCR was performed to determine the mRNA level
of GP73. Briefly, total RNA was extracted from 40 pairs
of matched gastric tumorous and adjacent non-tumorous
mucosal tissue specimens, using Trizol (Invitrogen,
Camarillo, USA) according to the manufacturer’s instruc-
tions. cDNA synthesis was carried out with the PrimeScript
1st Strand cDNA Synthesis kit (Takara,DaLian, China),
using 1 μg of total RNA as the template and OligodT
primer under 65°C, 5 minutes, 42°C, 60 minutes and 70°C,
10 minutes of reverse transcription. The resulting cDNA
was amplified by qPCR using specific primers with SYBR
Premix Ex Taq (Takara, DaLian, China). GAPDH was
used as an internal control. Primers for GP73 were
5′-GCAAAGCAACATCTTCCCTA-3′ (sense) and 5′-
CCACAACAAACTTGCCCTC-3′ (antisense). Primers
for GAPDH were 5′- TGAAGGTCGGAGTCAACGG-
3′ (sense) and 5′- CTGGAAGATGGTGATGGGATT-
3′ (antisense). PCR parameters were as follows: 95°C
for 5 minutes, followed by 40 cycles of 95°C for 10s,
60°C for 20s and 72°C for 20s. At the end of the PCR
cycles, melting curve analysis was performed. The relative
expression of GP73 to GAPDH was calculated using
2-ΔCT method.
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Western blotting was performed to investigate GP73 pro-
tein level in 5 of 41 pairs of gastric tumorous tissue and
adjacent non-tumorous mucosal tissue. Protein was iso-
lated from tissues samples following the RNA extraction.
And approximately 30 μg of protein was separated on 10%
polyacrylamide gel for two hours. After being trans-
ferred to a polyvinylidenedifluoride (PVDF) membrane (GE
Healthcare, Fairfield, Connecticut, USA), the samples were
probed with primary antibodies against GP73 (1:2,000,
Sigma, St. Louis, MO, USA) and β-actin (1:5,000, Sigma,
USA) at 4°Covernight. After incubating with secondary
antibody (1:5,000, CapitalBio, Beijing, China) for 2h, the
membranes were treated with electrochemiluminescence
(ECL) reagent (Generay, Shanghai, China) and exposed to
autoradiographicfilms.Immunohistochemical staining
Immunohistochemical staining was performed by the
standard method. Briefly, 52 cases of paraffin-embedded
gastric tumors tissues and 10 cases of adjacent non-
tumorous mucosal tissue controls were cut at 5 μm
thick and placed on microscopic slides and dried in a
60°C oven for 2h. Then, the sections were de-paraffinized
in xylene, rehydrated using a gradient of ethanol concentra-
tions, microwaved in 10 mM citrate buffer for 15 minutes
to retrieve antigen, blocked with 3% hydrogen peroxide for
10 minutes to inhibit endogenous peroxidase activity
and incubated with 10% goat non-immune serum for
20 minutes to reduce background non-specific staining.
After that, the sections were incubated with the rabbit
anti-GP73 polyclonal antibody (Abcam, Cambridge, UK)
(1:100 dilution) at 4°C overnight, then incubated with
biotin-labeled secondary antibody (Invitrogen,USA) at
room temperature for 20 minutes, followed by incuba-
tion with HRP-conjugated streptavidin (Invitrogen,
USA) at room temperature for 20 minutes. Then, color
development was performed with a DAB Substrate
Kit (Dako, Carlsbad, USA). Finally, the sections were
counterstained with hematoxylin, dehydrated, cleared
and mounted.Evaluation of the immunohistochemicalstainings
The immunohistochemicalstainings of GP73 were scored
by two pathologists independently, based on the intensity
and the proportion of positively stained cells. Staining
intensity was evaluated with a four-tiered grading system:
0 = negative, 1= weak, 2 = moderate and 3 = strong. The
percentage of positive cells were scored as follows: 0 for
no cell stained, 1 for 1% to 25% of cells stained, 2 for 26 to
50% of cells stained, 3 for 51 to 75% of cells stained and 4
for more than 75% of cells stained. Scores for intensity
and percentage of positive cells were multiplied. Scores ≤3was used to define tumors with low GP73 expression and
scores ≥4 with high GP73 expression.Statistical analysis
Statistical analysis was performed using SPSS software
13.0 (SPSS, Inc., Chicago, IL, USA). The paired-samples
t-test was used to analyze the differences of GP73 mRNA
expression between tumor and non-tumorous tissues. Chi-
square test was applied to assess the statistical significance
of the associations between GP73 expression and clinico-
pathological parameters. P<0.05 was considered statistically
significant.Results
GP73 expression level in gastric tumor and non-tumorous
tissue
GP73 mRNA expression was significantly decreased in
gastric tumor tissues compared to the adjacent non-
tumorous tissues (33/41; 80.5%). The expression levels of
GP73 relative to GAPDH were much lower in gastric tu-
morous tissues (0.259 ± 0.308) than that in non-tumorous
mucosal tissues (0.584 ± 0.523; P<0.01; Figure 1). Consist-
ent with RT-qPCR, GP73 protein level in gastric tumor
samples was significantly lower than that of non-tumorous
samples, which was tested by Western blotting (Figure 2).Correlation between GP73 protein expression and
clinicopathologic parameters
IHC showed that GP73 was highly expressed in adjacent
non-tumorous mucosal tissue, but decreased or even ab-
sent in gastric tumorous tissues. In non-tumorous mu-
cosa, strong diffuse cytoplasmic staining could be seen in
cells located at the surface of the glandular and foveolar
compartment (Figure 3A). In tumor tissues, GP73 expres-
sion was mainly expressed in a distinct semi-granular
dot-like staining pattern (Figure 3B, C). Only a few gas-
tric tumor tissues were found with strong expression of
GP73 (Figure 3D).
The correlation between expression of GP73 protein
and clinical variables is shown in Table 2. The GP73
expression level was significantly related to the gender
of patients (P = 0.027) and differentiation (P = 0.049).
The expression of GP73 in poorly differentiated gastric
tumors was much lower than that in moderately differ-
entiated gastric tumors. A total of 21 out of 30 poorly
differentiated gastric tumor cases showed low GP73 ex-
pression, while in moderately differentiated gastric tumor
cases it was only 9/22. Also, the expression of GP73 in
male patients was down-regulated more frequently than
that in female patients. There was no significant correl-
ation between GP73 expression and other clinicopatho-
logic parameters.
Figure 1 GP73 mRNA expression in gastric tumorous tissues and adjacent non-tumorous mucosal tissues.
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Recently, several studies showed that GP73 is over-
expressed in some cancers, including hepatocellular car-
cinomas, bile duct carcinomas, lung cancer, prostate
cancer and seminomas [9-15]. In hepatocellular carcin-
omas, high-expression of GP73 was associated with tumor
size, differentiation, grade and vein invasion [7-9]. In bile
duct carcinomas, GP73 expression correlated with patient
age and survival [11]. In lung cancer, GP73 expression
was associated with tumor histology and patient gender;
its expression in adenocarcinoma was significantly higher
than in other types of lung cancer [12]. However, no
correlation with clinicopathological parameters has been
found in prostate cancer and seminomas [13,15]. GP73
also has been found down-regulated in clear cell RCCs,
which is the most common histological subtype of renal
cell cancer, while its expression in papillary and chromo-
phobe RCC was strong [18]. In the present study, we
found that both GP73 mRNA and protein levels were
highly expressed in non-tumorous gastric mucosas, which
were opposite to most previous studies in other cancers.
The knowledge of GP73’s function still remains limited.
So far, we know that GP73 is essential for liver and kidneyFigure 2 GP73 protein level in gastric tumorous samples and adjacen
tumorous samples and adjacent non-tumorous mucosal samples. B) GP7
non-tumorous mucosal samples. C) gastric cancer; N: normal).to maintain normal function and appearance. It is also
known that GP73 may function in assisting in protein
transportation and secretion. One such protein, sCLU, has
already been identified. sCLU could prevent apoptosis and
is over-expressed in various cancers. GP73 could interact
with sCLU through coiled-coil domain and assist trans-
portation and secretion of sCLU, which may explain the
association between high expressed GP73 and the aggres-
sive behavior of hepatocellular carcinomas [3]. In hepato-
cellular carcinoma (HCC), the over-expression of GP73
was not only detected in cancer tissues but also in pa-
tients’ serum, which indicated the significant increase in
GP73 levels would provide a marker for early detection.
Some reports even stated that GP73 is a better marker
than AFP for diagnosing HCC [10,11,18,21]. However,
what is the function of GP73 in stomach and why would
it be down-regulated in gastric cancer? This is still un-
clear. GP73 is an epithelial cell-specific protein and
highly expressed in numerous normal human tissues,
especially in the colon and stomach. It is also predomin-
ately expressed in the small intestine, colon and stom-
ach of mice [22]. Consistent with these studies, we also
found that GP73 was highly expressed by cells locatedt non-tumorous mucosal samples. A) GP73 protein level in gastric
3 mRNA level in the same gastric tumorous samples and adjacent
Figure 3 GP73 protein expression in gastric tumorous tissues and adjacent non-tumorous mucosal tissues. A) Strong expression of GP73
in non-tumorous tissues. B) Weak expression of GP73 in gastric tumorous tissues. C) Moderate expression of GP73 in gastric tumorous tissues.
D) Strong expression of GP73 in gastric tumorous tissues. a,b,c,d: original magnification 100×. A,B,C,D: original magnification 200×.
Table 2 Relationship of GP73 expression with
pathological parameters of tumor
Clinical parameters GOLPH2 P-value
Low High
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of normal human gastric mucosa. Since the highest ex-
pression of GP73 is in epithelial cells of digestive organs,
it is reasonable to presume that it may play some import-
ant, unknown roles in the digestive system.
We also found the expression of GP73 was associated
with tumor differentiation. The expression of GP73 in
poorly differentiated gastric tumors was much lower
than that in moderately differentiated gastric tumors. It
was reported that knock-down of GP73 in HepG2.2.15
cells could cause a reduction in the surface area of the
Golgi complex. Since the size and development of the
Golgi complex are positively correlated with tumor dif-
ferentiation, some researchers hypothesized that GP73
expression might be associated with maintaining the
structural integrity of the Golgi complex during onco-
genesis [23,24]. Recent studies demonstrated that loss of
GP73 caused up-regulation of WT1, which may promote
glomus formation and inhibit pronephric tubule differ-
entiation. It suggested that GP73 plays an important role
in pronephros development and differentiation [25]. In
hepatocellular carcinoma, GP73 protein was strongly
associated with tumor size, vein invasion and tumor dif-
ferentiation, suggesting GP73 expression is correlated
with the aggressive behavior of cancer [10]. Moreover,
the expression of GP73 was also associated with patient
gender. Male patients showed low GP73 expression more
frequently than female patients. A similar phenomenon
has also been reported in lung cancer. Female patients
had a higher expression of GP73 than male patients [12].
It is also reported that phenotypic changes observed in
mice with truncated GP73 C-terminus are gender-
dependent [4]. One explanation is that GP73 mRNA is
regulated by estrogens and calcitriol [26]. Our work
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under hormonal control.
Conclusion
In conclusion, we found that both the GP73 mRNA and
protein level was significantly down-regulated in gastric
tumorous tissues compared to the non-tumorous mucosa,
and the expression of GP73 was associated with tumor
differentiation and patient gender. Our further work will
focus on investigating the function and the regulation
mechanism of GP73 in the stomach.
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